Investigating the impact of FOXA1 phase separation on metastasis formation in prostate cancer

Ended Project Grant Awarded Last action

Award ID
HT94252410107
Recipient
Awarding agency
Obligated
$119,000

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Israel

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $119,000 Project Grant to Technion Research & Development Foundation LTD., a foreign-owned for-profit organization based in Israel. The grant will fund research investigating the impact of FOXA1 phase separation on metastasis formation in prostate cancer. The research will be conducted from Sep 1, 2024 to Aug 31, 2026. Technion Research & Development Foundation, which has previously collaborated with universities on federal grants for biomedical research, will deliver the products and services associated with this award to address military medical priorities.

Quick answers

Who received award HT94252410107?

HT94252410107 was awarded to Technion Research & Development Foundation LTD. by Defense Health Agency (Department of Defense) on September 1, 2024.

How much is award HT94252410107 worth?

$119,000 has been obligated on HT94252410107.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login